Liquid Biopsy Scores Immunotherapy Effectiveness
Circulating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read More
Search Results for: lung cancer
Prognostic Information Provided by Biodesix Proteomic Test Alters Oncologists’ Treatment Decisions
A blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions and reduce costs associated with overtreatment in lung cancer.
Read More
New Data Show Biodesix Blood Test Reliably Detects Additional Mutations in Patients with NSCLC
The highly multiplexed ddPCR-based assay is currently in use by biopharma partners.
Read MoreProteocyte AI Leverages Proscia Digital Pathology Platform to Predict Risk of Oral Cancer
Proscia and Proteocyte AI have signed an agreement to integrate Proscia’s technology with the Straticyte test for predicting the risk of progression to oral cancer.
Read MoreQiagen Launches Liquid Biopsy Kits for Prostate, Lung Cancers
Qiagen has launched two novel liquid biopsy panels for the evaluation of circulating tumor cells, in the growing field of research into the molecular mechanisms of prostate and lung cancers.
Read More